In the last trading session, 2.75 million Summit Therapeutics Inc. (NASDAQ:SMMT) shares changed hands as the company’s beta touched -0.85. With the company’s per share price at $1.87 changed hands at -$0.04 or -2.09% during last session, the market valuation stood at $1.33B. SMMT’s last price was a discount, traded about -209.09% off its 52-week high of $5.78. The share price had its 52-week low at $0.66, which suggests the last value was 64.71% up since then. When we look at Summit Therapeutics Inc.’s average trading volume, we note the 10-day average is 1.16 million shares, with the 3-month average coming to 1.69 million.

Analysts gave the Summit Therapeutics Inc. (SMMT) stock a consensus recommendation rating of a Hold, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended SMMT as a Hold, 0 felt it is a Buy and 0 rated the stock as Underweight. Summit Therapeutics Inc.’s EPS for the current quarter is expected to be $0.

Summit Therapeutics Inc. (NASDAQ:SMMT) trade information

Instantly SMMT was in red as seen at the end of in last trading. With action 21.43%, the performance over the past five days has been green. The drop to weekly highs of 1.9800 on Friday, 09/15/23 subtracted -2.09% to the stock’s daily price. The company’s shares are showing year-to-date downside of -56.00%, with the 5-day performance at 21.43% in the green. However, in the 30-day time frame, Summit Therapeutics Inc. (NASDAQ:SMMT) is 5.06% up. Looking at the short shares, we see there were 10.53 million shares sold at short interest cover period of 9.16 days.

The consensus price target for the stock as assigned by Wall Street analysts is $4.00, meaning bulls need an upside of 53.25% from its current market value. According to analyst projections, SMMT’s forecast low is $4.00 with $4.00 as the target high. To hit the forecast high, the stock’s price needs a -113.9% plunge from its current level, while the stock would need to soar -113.9% for it to hit the projected low.

Summit Therapeutics Inc. (SMMT) estimates and forecasts

Year-over-year growth is forecast to reach -92.30% down from the last financial year.

The company’s revenue for the corresponding quarters a year ago was $4.55 million and $192k respectively.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 27.40%. The 2023 estimates are for Summit Therapeutics Inc. earnings to increase by 57.60%.

SMMT Dividends

Summit Therapeutics Inc. is expected to release its next quarterly earnings report in October.

Summit Therapeutics Inc. (NASDAQ:SMMT)’s Major holders